Previous studies from our institution have shown that serum secretory phospholipase A2 (sPLA2) levels are markedly increased in sickle cell disease (SCD) patients with acute chest syndrome (ACS)[1][1] and that sequential measurements of sPLA2 are useful in predicting the subsequent development of